microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity

被引：0
|
作者：
Elizabeth C Martin
Lyndsay V Rhodes
Steven Elliott
Adrienne E Krebs
Kenneth P Nephew
Erik K Flemington
Bridgette M Collins-Burow
Matthew E Burow
机构：
[1] Tulane University,Department of Medicine
[2] Tulane University,Section of Hematology and Medical Oncology
[3] Tulane University,Department of Pharmacology
[4] Tulane University,The Center for Bioenvironmental Research
[5] Indiana University School of Medicine,Department of Pathology
来源：
Molecular Cancer | / 13卷
关键词：
miR-155; mTOR; breast cancer; miRNA; Estrogen receptor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 43 条
  • [1] microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RADOO1 sensitivity
    Martin, Elizabeth C.
    Rhodes, Lyndsay V.
    Elliott, Steven
    Krebs, Adrienne E.
    Nephew, Kenneth P.
    Flemington, Erik K.
    Collins-Burow, Bridgette M.
    Burow, Matthew E.
    MOLECULAR CANCER, 2014, 13
  • [2] Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis
    Parikh, Sameer A.
    Kantarjian, Hagop M.
    Richie, Mary Ann
    Cortes, Jorge E.
    Verstovsek, Srdan
    LEUKEMIA & LYMPHOMA, 2010, 51 (02) : 269 - 274
  • [3] Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer
    Manegold, Philipp C.
    Paringer, Carmen
    Kulka, Ulrike
    Krimmel, Klaus
    Eichhorn, Martin E.
    Wilkowski, Ralf
    Jauch, Karl-Walter
    Guba, Markus
    Bruns, Christiane J.
    CLINICAL CANCER RESEARCH, 2008, 14 (03) : 892 - 900
  • [4] A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
    Thomas Decker
    Michael Sandherr
    Katharina Goetze
    Madlen Oelsner
    Ingo Ringshausen
    Christian Peschel
    Annals of Hematology, 2009, 88 : 221 - 227
  • [5] A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
    Decker, Thomas
    Sandherr, Michael
    Goetze, Katharina
    Oelsner, Madlen
    Ringshausen, Ingo
    Peschel, Christian
    ANNALS OF HEMATOLOGY, 2009, 88 (03) : 221 - 227
  • [6] The mTOR (mammalian target of rapamycin) inhibitor RAD001 (Everolimus) is safe and reduces proliferation in postmenopausal women with breast cancer
    Macaskill, E. J.
    Bartlett, J. M. S.
    Renshaw, L.
    Faratian, D.
    White, S.
    Campbell, F. M.
    Young, O.
    Stumm, M.
    Thomas, J.
    Barber, M. D.
    Dixon, J. M.
    EJC SUPPLEMENTS, 2007, 5 (03): : 30 - 30
  • [7] Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma
    Xu, Zi-Zhen
    Wang, Wen-Fang
    Fu, Wan-Bin
    Wang, Ai-Hua
    Liu, Zhi-Yin
    Chen, Li-Yun
    Guo, Pei
    Li, Jun-Min
    LEUKEMIA & LYMPHOMA, 2014, 55 (05) : 1151 - 1157
  • [8] The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study
    E. J. Macaskill
    J. M. S. Bartlett
    V. S. Sabine
    D. Faratian
    L. Renshaw
    S. White
    F. M. Campbell
    O. Young
    L. Williams
    J. S. Thomas
    M. D. Barber
    J. M. Dixon
    Breast Cancer Research and Treatment, 2011, 128 : 725 - 734
  • [9] The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study
    Macaskill, E. J.
    Bartlett, J. M. S.
    Sabine, V. S.
    Faratian, D.
    Renshaw, L.
    White, S.
    Campbell, F. M.
    Young, O.
    Williams, L.
    Thomas, J. S.
    Barber, M. D.
    Dixon, J. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (03) : 725 - 734
  • [10] Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
    Yee, Karen W. L.
    Zeng, Zhihong
    Konopleva, Marina
    Verstovsek, Srdan
    Ravandi, Farhad
    Ferrajoli, Alessandra
    Thomas, Deborah
    Wierda, William
    Apostolidou, Efrosyni
    Albitar, Maher
    O'Brien, Susan
    Andreeff, Michael
    Giles, Francis J.
    CLINICAL CANCER RESEARCH, 2006, 12 (17) : 5165 - 5173
12345